Skip to main content
. 2022 Jan 20;126(9):1346–1354. doi: 10.1038/s41416-022-01702-z

Table 3.

Results of the mulitvariable cox-regression.

QoL domain Univariate Model 1 Model 2 Model 3
Per 10 points
HR (95% CI)		 Per 10 points
HR (95% CI)		 Quartiles [range] (%) Deceased (%) Model
HR (95% CI)		 Clinical important restrictions or symptoms [range] (%) Deceased (%) Model
HR (95% CI)
Summary score 0.68 (0.60–0.76) 0.74 (0.64–0.85) 4.Qu. [>86.4–100] 271 (25.1) 10 (3.7) ref. n.a. n.a. n.a. n.a.
3.Qu. [>73.6–86.4] 271 (25.1) 16 (5.9) 1.01 (0.43–2.38)
2.Qu. [>57.8–73.6] 268 (24.8) 39 (14.6) 2.27 (1.06–4.88)
1.Qu. [0–57.8] 270 (25.0) 60 (22.0) 3.65 (1.73–7.69)
Global health 0.69 (0.62–0.76) 0.73 (0.64–0.82) 4.Qu. [83.3–100] 262 (23.9) 5 (1.9) ref. n.a. n.a. n.a. n.a.
3.Qu. [66.7–75.0] 289 (26.3) 26 (9.0) 3.11 (1.12–8.59)
2.Qu. [50.0–58.3] 264 (24.1) 34 (12.9) 3.58 (1.31–9.78)
1.Qu. [0–41.7] 282 (25.7) 61 (21.6) 8.29 (3.13–22.00)
Physical functioning 0.77 (0.71–0.83) 0.82 (0.74–0.89) 4.Qu. [93.3–100] 336 (30.5) 16 (4.8) ref. No [86.7–100] 447 (40.6) 24 (5.4) ref.
3.Qu. [80.0–91.7] 231 (21.0) 18 (7.8) 1.09 (0.52–2.28)
2.Qu. [58.3–73.3] 248 (22.5) 32 (12.9) 2.42 (1.23–4.78) Yes [0–80.0] 653 (59.4) 102 (15.6) 2.35 (1.43–3.87)
1.Qu. [0–53.3] 285 (25.9) 60 (21.1) 2.89 (1.52–5.51)
Role functioning 0.82 (0.77–0.88) 0.91 (0.84–0.97) 4.Qu. [100] 240 (21.8) 10 (4.2) ref. No [66.7–100] 542 (49.3) 33 (6.1) ref.
3.Qu. [66.7–83.3] 302 (27.5) 23 (7.6) 0.99 (0.45–2.18)
2.Qu. [33.3–50.0] 315 (28.6) 44 (14.0) 1.53 (0.73–3.23) Yes [0–50.0] 558 (50.7) 93 (16.7) 1.67 (1.07–2.62)
1.Qu. [0–16.7] 243 (22.1) 49 (20.2) 1.85 (0.86–3.98)
Emotional functioning 0.89 (0.82–0.95) 0.89 (0.81–0.97) 4.Qu. [83.3–100] 302 (27.5) 27 (8.9) ref. No [75.0–100] 409 (37.2) 35 (8.6) ref.
3.Qu. [66.7–77.8] 239 (21.7) 16 (6.7) 0.73 (0.38–1.43)
2.Qu. [41.7–58.3] 331 (30.1) 43 (13.0) 1.26 (0.74–2.14) Yes [0–66.7] 690 (62.8) 90 (13.0) 1.53 (0.98–2.37)
1.Qu. [0–33.3] 227 (20.7) 39 (17.2) 2.07 (1.18–3.63)
Cognitive functioning 0.92 (0.86–0.98) 0.95 (0.89–1.02) 4.Qu. [100] 452 (41.1) 41 (9.1) ref. No [83.3–100] 672 (61.0) 65 (9.7) ref.
3.Qu. [83.3] 220 (20.0) 24 (10.9) 1.32 (0.75–2.33)
2.Qu. [66.7] 205 (18.6) 28 (13.7) 2.11 (1.22–3.62) Yes [0–66.7] 429 (39.0) 61 (14.2) 1.52 (1.02–2.24)
1.Qu. [0–50.0] 224 (20.3) 33 (14.7) 1.42 (0.86–2.35)
Social functioning 0.80 (0.75–0.86) 0.88 (0.81–0.94) 4.Qu. [100] 236 (21.5) 6 (2.5) ref. No [66.7–100] 596 (54.2) 32 (5.4) ref.
3.Qu. [66.7–83.3] 360 (32.7) 26 (7.2) 1.9 (0.75–4.82)
2.Qu. [33.3–50.0] 283 (25.7) 45 (15.9) 2.72 (1.09–6.82) Yes [0–50.0] 504 (45.8) 94 (18.7) 2.07 (1.33–3.21)
1.Qu. [0–16.7] 221 (20.1) 49 (22.2) 4.23 (1.71–10.44)
Fatigue 1.22 (1.16–1.29) 1.17 (1.10–1.25) 1.Qu. [0–16.7] 238 (21.6) 9 (3.8) ref. No[0–33.3] 539(49.0) 29(5.4) ref.
2.Qu. [22.2–33.3] 301 (27.4) 20 (6.6) 1.57 (0.68–3.64)
3.Qu. [44.4–55.6] 229 (20.8) 27 (11.8) 2.34 (1.04–5.26) Yes [44.4–100] 561 (51.0) 97 (17.3) 2.58 (1.64–4.06)
4.Qu. [66.7–100] 332(30.2) 70 (21.1) 4.21 (1.98–8.94)
Nausea vomiting 1.17 (1.11–1.24) 1.18 (1.10–1.27) 1.Qu. [0] 799 (72.6) 63 (7.9) ref. No [0] 799 (72.6) 63 (7.9) ref.
2.Qu. [16.7] 153 (13.9) 27 (17.6) 1.57 (0.93–2.66)
3.Qu. [33.3] 77 (7.0) 19 (24.7) 2.74 (1.53–4.90) Yes [16.7–100] 302 (27.4) 63 (20.9) 2.17 (1.45–3.25)
4.Qu. [50.0–100] 72 (6.5) 17 (23.6) 3.01 (1.63–5.55)
Pain 1.14 (1.09–1.19) 1.14 (1.08–1.20) 1.Qu. [0] 343 (31.2) 24 (7.0) ref. No [0–16.7] 490 (44.5) 36 (7.3) ref.
2.Qu. [16.7] 147 (13.4) 12 (8.2) 1.19 (0.56–2.56)
3.Qu. [33.3–50.0] 334 (30.3) 36 (10.8) 1.55 (0.87–2.74) Yes [33.3–100] 611 (55.5) 90 (14.7) 2.02 (1.30–3.15)
4.Qu. [66.7–100] 277 (25.2) 54 (19.5) 2.99 (1.72–5.19)
Dyspnoea 1.17 (1.12–1.23) 1.09 (1.04–1.15) 1.Qu. [0] 554 (50.7) 38 (6.9) ref. No [0] 554 (50.7) 38 (6.9) ref.
2.Qu. [33.3] 299 (27.4) 32 (10.7) 1.22 (0.72–2.07)
3.Qu. [66.7] 187 (17.1) 38 (20.3) 2.03 (1.24–3.34) Yes [33.3–100] 539 (49.3) 87 (16.1) 1.68 (1.10–2.57)
4.Qu. [100] 53 (4.8) 17 (32.1) 2.24 (1.16–4.31)
Insomnia 1.05 (0.995–1.1) 1.04 (0.98–1.09) 1.Qu. [0] 358 (32.6) 36 (10.1) ref. No [0–33.3] 710 (64.7) 71 (10.1) ref.
2.Qu. [33.3] 352 (32.1) 36 (10.2) 0.97 (0.57–1.66)
3.Qu. [66.7] 245 (22.3) 32 (13.1) 1.19 (0.69–2.03) Yes [66.7–100] 387 (35.3) 54 (14.0) 1.28 (0.86–1.90)
4.Qu. [100] 142 (12.9) 22 (15.5) 1.41 (0.76–2.6)
Appetite loss 1.18 (1.13–1.23) 1.15 (1.09–1.21) 1.Qu. [0] 722 (65.6) 49 (6.8) ref. No [0–33.3] 930 (84.5) 82 (8.8) ref.
2.Qu. [33.3] 208 (18.9) 33 (15.9) 2.10 (1.28–3.44)
3.Qu. [66.7] 127 (11.5) 31 (24.4) 3.56 (2.12–5.99) Yes [66.7–100] 171 (15.5) 44 (25.7) 2.68 (1.76–4.07)
4.Qu. [100] 44 (4.0) 13 (29.5) 3.43 (1.71–6.88)
Constipation 1.12 (1.07–1.17) 1.07 (1.01–1.13) 1.Qu. [0] 768 (70.0) 66 (8.6) ref. No [0–33.3] 949 (86.5) 90 (9.5) ref.
2.Qu. [33.3] 181 (16.5) 24 (13.3) 1.12 (0.67–1.87)
3.Qu. [66.7] 91 (8.3) 25 (27.5) 1.96 (1.16–3.31) Yes [66.7–100] 148 (13.5) 36 (24.3) 1.80 (1.16–2.79)
4.Qu. [100] 57 (5.2) 11 (19.3) 1.66 (0.82–3.37)
Diarrhea 1.08 (1.03–1.14) 1.06 (0.99–1.13) 1.Qu. [0] 814 (74.1) 78 (9.6) ref. No[0] 814 (74.1) 78 (9.6) ref.
2.Qu. [33.3] 167 (15.2) 30 (18.0) 1.45 (0.89–2.36)
3.Qu. [66.7] 85 (7.7) 11 (12.9) 1.15 (0.56–2.36) Yes [33.3–100] 285 (25.9) 48 (16.8) 1.44 (0.96–2.18)
4.Qu. [100] 33 (3.0) 7 (21.2) 2.12 (0.87–5.15)
Financial difficulties 1.06 (1.02–1.11) 1.07 (1.01–1.13) 1.Qu. [0] 600 (54.8) 54 (9.0) ref. No [0] 600 (54.8) 54 (9.0) ref.
2.Qu. [33.3] 236 (21.6) 29 (12.3) 1.76 (1.04–2.98)
3.Qu. [66.7] 164 (14.9) 30 (18.3) 1.99 (1.18–3.36) Yes [33.3–100] 494 (45.2) 71 (14.4) 1.81 (1.18–2.78)
4.Qu. [100] 94 (8.6) 12 (12.8) 1.55 (0.72–3.3)

Variables in the model: sex, age at baseline, employment status at baseline, school education, sarcoma type, tumour site, grading at diagnosis, tumour size at diagnosis, time since diagnosis, tumour recurrence until baseline, metastasis until baseline, disease status at baseline, comorbidities, surgery, chemotherapy, radiotherapy until baseline. Boldface = statistically significant at p < 0.05.

HR hazard ratio, 95% CI 95% confidence intervall, ref reference, n.a. not available.